Paul-Satyaseela Maneesh, Solanki Shakti Singh, Sathishkumar Devarajan, Bharani Thirunavukkarasu, Magesh Vijayan, Rajagopal Sriram
Anti-infectives Discovery, Department of Microbiology, Orchid Research Laboratories Ltd, 476/14, OMR, Sholinganallur, Chennai 600 119 (TN), India.
J Antimicrob Chemother. 2009 Oct;64(4):797-800. doi: 10.1093/jac/dkp300. Epub 2009 Aug 18.
In the pursuit of developing a second-generation oxazolidinone, we have identified OCID0050 as a novel oxazolidinone with enhanced activity against bacterial strains resistant to methicillin, vancomycin and linezolid.
MIC and MBC determinations were performed according to CLSI guidelines. Linezolid-resistant bacterial strains were generated in-house; inoculum effect, pH effect and kill kinetics experiments were performed as per standard protocols.
OCID0050 demonstrated better inhibitory potency against many of the tested clinically significant strains by generally showing 2-4-fold lower MICs than linezolid. In addition, it has higher inhibitory activity against linezolid-resistant strains.
在开发第二代恶唑烷酮的过程中，我们确定OCID0050是一种新型恶唑烷酮，对耐甲氧西林、万古霉素和利奈唑胺的细菌菌株具有增强的活性。
根据CLSI指南进行最低抑菌浓度（MIC）和最低杀菌浓度（MBC）测定。利奈唑胺耐药细菌菌株在内部产生；按照标准方案进行接种物效应、pH效应和杀菌动力学实验。
OCID0050对许多测试的临床重要菌株表现出更好的抑制效力，其MIC通常比利奈唑胺低2至4倍。此外，它对利奈唑胺耐药菌株具有更高的抑制活性。
